Emil Kumar
YOU?
Author Swipe
View article: Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects
Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects Open
Significant strides have been made in the treatment of follicular lymphoma, leading to improvements in long‐term patient outcomes. However, the disease's heterogeneity presents challenges in selecting the optimal therapy at each stage of t…
View article: Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK Open
Background After approval of axicabtagene ciloleucel (axi-cel) as second-line (2L) treatment for large B-cell lymphoma (LBCL) relapsed or refractory within 12 months of first-line (1L) chemoimmunotherapy (CIT), access to 2L axi-cel in the …
View article: <i>CREBBP</i> histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
<i>CREBBP</i> histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma Open
Summary Despite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack of biomarker‐directed therapeutic approaches in routine clinical practice, with the notable exception of the EZH2 inhibitor tazemeto…
View article: Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma Open
Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but …
View article: KDM5 inhibition offers a novel therapeutic strategy for the treatment of <i>KMT2D</i> mutant lymphomas
KDM5 inhibition offers a novel therapeutic strategy for the treatment of <i>KMT2D</i> mutant lymphomas Open
Loss-of-function mutations in KMT2D are a striking feature of germinal center (GC) lymphomas, resulting in decreased histone 3 lysine 4 (H3K4) methylation and altered gene expression. We hypothesized that inhibition of the KDM5 family, whi…
View article: Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation
Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation Open
Summary Follicular lymphoma (FL) represents a heterogeneous disease both clinically and biologically. The pathognomonic t(14;18) translocation can no longer be thought of as the primary genetic driver, with increasing recognition of the bi…
View article: Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy
Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy Open
Summary Haematology patients receiving chemo‐ or immunotherapy are considered to be at greater risk of COVID‐19‐related morbidity and mortality. We aimed to identify risk factors for COVID‐19 severity and assess outcomes in patients where …
View article: KDM5 inhibition offers a novel therapeutic strategy for the treatment of<i>KMT2D</i>mutant lymphomas
KDM5 inhibition offers a novel therapeutic strategy for the treatment of<i>KMT2D</i>mutant lymphomas Open
Loss-of-function mutations in KMT2D are a striking feature of the germinal centre (GC) lymphomas, resulting in decreased H3K4 methylation and altered gene expression. We hypothesised that inhibition of the KDM5 family, which demethylates H…
View article: PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
PF513 MUTATIONS AFFECTING THE CREBBP HAT DOMAIN PREDICT RESPONSE TO MTOR INHIBITORS EVEROLIMUS AND TEMSIROLIMUS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA Open
Background: With an expanding array of novel treatment options in follicular lymphoma (FL), we largely lack effective biomarkers to predict response in this molecularly heterogeneous disease. Activating mutations focused on components of t…
View article: Follicular lymphoma genomics
Follicular lymphoma genomics Open
Take home messages The genetic landscape of follicular lymphoma (FL) is skewed toward frequent mutations in epigenetic regulators. Divergent clonal evolution from a therapy-evading common progenitor cell is proposed as the predominant mech…
View article: Precision medicine and lymphoma
Precision medicine and lymphoma Open
Purpose of review The treatment of the germinal center lymphomas, diffuse large B cell (DLBCL) and follicular lymphoma, has changed little beyond the introduction of immunochemotherapies. However, there exists a substantial group of patien…
View article: Clinical characteristics and outcomes of HIV-associated immune complex kidney disease
Clinical characteristics and outcomes of HIV-associated immune complex kidney disease Open
These findings suggest a pathogenic role for HIV replication in the development of HIVICK and that ART may improve kidney function in patients who have detectable HIV RNA at the time of HIVICK diagnosis. Our data also suggest that IgA neph…